



**Drug Name:** Kisqali-Femara Co-Pack (ribociclib)  
**Date:** 9-2018

<b>Drug Name: Kisqali-Femara Co-Pack</b>	
<b>Required Medical Information:</b>	<ul style="list-style-type: none"><li>• Prescriber is an oncologist</li><li>• Drug is being used for a medically-accepted indication (approved by the FDA or compendia-supported)<ul style="list-style-type: none"><li>○ Diagnosis of advanced or metastatic breast cancer</li><li>○ Hormone receptor (HR)-positive breast cancer</li><li>○ Human epidermal growth factor receptor 2 (HER2)-negative breast cancer</li><li>○ Use as initial endocrine therapy</li><li>○ Member is postmenopausal</li></ul></li></ul>
<b>Quantity Limit:</b>	200-2.5: 49 tablets per 28 days 400-2.5: 70 tablets per 28 days 600-2.5: 91 tablets per 28 days
<b>Coverage Duration:</b>	12 months